| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Product revenue | 123 | 317 | 45 | 59 |
| Sales and marketing | - | - | 10 | 143 |
| Cost of sales | 112 | 302 | 33 | - |
| Research and development | 655 | 697 | 601 | 557 |
| Sales and marketing | 25 | 0 | - | - |
| Cost of sales | - | - | - | 70 |
| General and administrative | 1,045 | 1,151 | 1,071 | 1,148 |
| Operating expenses | - | - | - | 1,918 |
| Total operating expenses | 1,837 | 2,150 | 1,715 | - |
| Operating loss | -1,714 | -1,833 | -1,670 | -1,859 |
| Interest income | 11 | 7 | 13 | - |
| Interest expense | 2 | 3 | 2 | - |
| Other income | 5 | 6 | - | - |
| Other (expense) income, net | - | - | - | -1 |
| Other income (expense), net | 14 | 10 | 11 | - |
| Net loss | -1,700 | -1,823 | -1,659 | -1,860 |
| Foreign currency translation adjustments | -2 | -1 | - | - |
| Net income (loss) available to common stockholders, basic | - | - | - | -1,860 |
| Comprehensive loss | -1,702 | -1,824 | -1,659 | - |
| Diluted eps | - | - | - | -0.12 |
| Diluted average shares | - | - | - | 15,017,591 |
| Basic and diluted net loss per share (in dollars per share) | -0.1 | -0.11 | -0.1 | -0.12 |
| Weighted average common shares outstanding, basic and diluted (in shares) | 17,033,109 | 15,918,979 | 15,918,979 | 15,017,591 |
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
Harvard Apparatus Regenerative Technology, Inc. (HRGN)